再鼎医药(09688.HK):治疗晚期胃肠道间质瘤新药获内地批准上市
再鼎医药(09688.HK)公布,国家药监局已批准擎乐(瑞派替尼)的新药上市申请,该药物为由Deciphera(DCPH.US)开发的一种开关调控酪氨酸激(酉每)抑制剂,用於治疗既往接受过包括伊马替尼在内的三种或以上激(酉每)抑制剂治疗的晚期胃肠道间质瘤成人患者。
公司与Deciphera於2019年6月订立独家授权协议,公司取得Deciphera若干专利及专有技术的独家授权,於大中华地区开发及商业化包括擎乐在内的产品,用於防治、预防、治疗、治愈或缓解任何人类疾病或病症的领域。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.